Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTACT: Phase 3 Study of Dimebon in Moderate-to-Severe Alzheimer's Disease with Neuropsychiatric Symptoms
2009-011799-31Phase 3Terminated
- Sponsor
- Medivation
- Start
- Jun 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Dimebon with Placebo (2 arms). Primary endpoint: Primary efficacy and safety endpoints. Started Jun 2009; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-011799-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011799-31.